IPP Bureau
Ayush Minister lays foundation stone for Heartfulness International Yoga academy
By IPP Bureau - January 04, 2022
The Academy endeavours to reach all levels of the society in creating programs that are accessible to one and all with training for Health Volunteers, Asha, Angavadi, school-teachers and students as part of life-skill development
Transcat acquires Tangent Labs for US $ 9 million
By IPP Bureau - January 04, 2022
Tangent offers ISO/IEC 17025-accredited calibrations and has labs located in both Indianapolis and Huntsville, Alabama
USFDA grants ILiAD Biotechnologies Fast Track Designation for pertussis vaccine
By IPP Bureau - January 04, 2022
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Amyris and ImmunityBio JV for next gen Covid-19 RNA vaccine
By IPP Bureau - January 04, 2022
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Alembic receives USFDA approval for Doxycycline Hyclate
By IPP Bureau - January 04, 2022
Doxycycline Hyclate Delayed Release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria
Kyverna Therapeutics announces licence agreement with NIH
By IPP Bureau - January 04, 2022
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
Combination of Covishield-Covaxin more effective: AIG hospital study
By IPP Bureau - January 04, 2022
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Domestic and emerging markets will drive pharma growth: ICRA
By IPP Bureau - January 04, 2022
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Dr Reddy’s molnupiravir priced at Rs 1,400 for a course
By IPP Bureau - January 04, 2022
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
Yokogawa invests in glycan production company GlyTech
By IPP Bureau - January 04, 2022
Partnering to build biosynthesis processes and a pharmaceutical production platform
Emcure to launch oral Covid-19 drug soon
By IPP Bureau - January 03, 2022
A toll-free helpline to be set up to help doctors and patients
Novavax submits data to U.S. FDA for Covid-19 EUA
By IPP Bureau - January 03, 2022
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
Ascletis expands ritonavir oral tablet production
By IPP Bureau - January 03, 2022
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
Snapdeal to promote Ayushman Bharat Digital Mission’s Heath ID
By IPP Bureau - January 03, 2022
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
U.S. FDA grants EUA for Pfizer-BioNTech booster for 12 years and older
By IPP Bureau - January 03, 2022
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
